AVM Biotechnology is a clinical-stage company focused on developing AVM0703, a proprietary formulation of concentrated dexamethasone designed to treat cancer and autoimmune diseases. The company targets patients with relapsed or refractory lymphoma and leukemia who have not responded to conventional treatments. AVM0703 activates and mobilizes supercharged gamma delta TCR invariant TCR bispecific T lymphocytes and Natural Killer T-like immune cells, which have unique immune response properties. These cells rapidly appear in the blood following a single dose and home to abnormal cells, including cancerous, infected, and autoreactive lymphocytes. The business operates in the biopharmaceutical market, primarily serving patients and healthcare providers. AVM Biotechnology generates revenue through clinical trials and potential future commercialization of AVM0703. The company is actively enrolling patients in a pivotal Phase 2 study at major cancer treatment centers in the US.

Keywords: AVM0703, dexamethasone, cancer, autoimmune diseases, immune cells, lymphoma, leukemia, clinical trials, biopharmaceutical, therapeutic.